Aims-To determine whether enzyme linked immunosorbent assay (ELISA) results for Borrelia burgdorferi require confirmation by immunoblotting and how immunoblotting may best be used in the diagnosis of Lyme disease. Methods-Over one year, all referrals for Lyme disease to a district general hospital with a large tick population in its catchment area were tested by ELISA. Positive, low positive and negative serum samples were subjected to immunoblotting and the reactive bands analysed. Results-In total, 633 samples were received; 38 were ELISA positive and 97 low positive. More serum samples were from rural (n = 356) than from urban (n = 277) areas but a higher percentage of serum samples from urban areas were ELISA positive. The ELISA results were confirmed by immunoblotting in 15/38 positive samples but in only four of 37 with a low positive titre. An IgM positive blot required a 41 kDa band plus . 1 specific band; for IgG a 41 kDa band plus > 2 specific bands were necessary. Five serum samples were IgM positive with a 41 kDa plus one or more other specific bands. For IgG blots, the best discrimination was seen with the 21, 31, 46, and 92 kDa bands. Nonspecific, weakly reacting bands at 55, 60 and 67 kDa were frequently seen. Infection was confirmed in four of six patients with arthritis, but in only one of 10 patients with erythema chronicum migrans. Conclusions-ELISA alone is insufficient for diagnosis. All 
Two decades after the identification of Lyme disease, it is disappointing that the role of laboratory diagnosis is minor and many feel that diagnosis should be based on clinical and epidemiological evidence of infection.' Laboratory diagnosis has depended on serological tests, immunofluorescence or enzyme linked immunosorbent assay (ELISA), which are widely regarded as lacking sensitivity, specificity and interlaboratory reproducibility. [2] [3] [4] How can laboratory diagnosis be improved? It has been suggested recently that ELISAs should be used as screening tests with confirmation of positive results by immunoblotting. 5 However, there is no standard protocol defining which immunoblot banding pattern is diagnostic2 and different criteria have been suggested by various groups.`9 Laboratory tests should also take into account the characteristics of the causative spirochaete Borrelia burgdoerfei,' such as delayed antibody response3 or lack of antibody production where there is prompt appropriate antibiotic treatment. 2 Lyme disease is endemic in the Scottish Highlands, an area in which there is a very large population of ticks (Ixodes ricinus) and many patients who recall a history oftick bites.'0 Laboratory analysis is often required in the diagnosis of Lyme disease, and there is a need to give more specific advice. Whereas classic erythema chronicum 'migrans (ECM) seen early in infection may be easy to diagnose clinically, the vague and less specific symptoms (arthritic, cardiac, neurological, etc) seen in late Lyme disease" require additional investigation.
Our laboratory has to be pragmatic and adopt a protocol for diagnosis which has scientific validity and satisfies the demands of users.
Methods
From September 1994 to August 1995, all serum samples from patients with symptoms regarded as consistent with Lyme disease were tested for antibodies directed against B burgdorferi at Raigmore Hospital NHS Trust, Inverness. The serum samples were received from general practitioners and hospital consultants.
CULTURE OF B BURGDORFERI
B burgdorferi (ACA-1) was cultured in BSK-H medium (Sigma, Poole, Dorset, UK) for seven days at 34°C. Cells from 50 ml medium were harvested by centrifugation at 3000 x g for 30 minutes and washed twice in phosphate buffered saline (PBS). After the final wash the cells were resuspended in 1S5 ml distilled water and stored at -70°C until used as antigen for immunoblotting.
ELISA All serum samples were tested routinely by ELISA for total antibody directed against B burgdorferi (Human Lyme EIA, Cambridge Biotech) following the manufacturer's instructions but with differences in interpretation. Serum samples were only reported as positive if the absorbance values were greater than twice the cut off level recommended by the manufacturer. Serum samples falling between the cut off and twice the cut off level were regarded as low positive. All positive serum samples were tested further for rheumatoid factor (Microgen, Camberley, UK) and antibody directed against Treponema pallidum (TPHA; Mast Laboratories, Liverpool, UK). disease has resulted in a significant increase in workload in laboratories.
Because of cross-reactions, especially with other spirochaetes, ELISA tests lack specificity."5 One report has suggested that only 16-3% of ELISA positive samples could be confirmed by immunoblotting.' The majority (97/135, 74%) of ELISA positive results in this study were in the low positive category. Applying criteria normally used for any other serological test, low positive results in a single specimen were not regarded as diagnostic, although further testing was recommended for patients with symptoms of recent onset. By modifying the manufacturer's criteria for a positive reaction, we were able to confirm ELISA positive results in 31% of patients. In contrast, the observation that results of only 11% of patients in the low positive group were confirmed by immunoblotting (x2 p<0-0l) provides some justification for the modification, especially as the low positive serum samples chosen for immunoblotting had a bias towards those patients with the most likely clinical symptoms. The finding that two patients with ELISA negative results were positive by immunoblotting confirms previous false negative reports for ELISA tests.' If ELISA tests are used for screening, patients with classic histories for Lyme disease or early in the illness may also need to be tested by immunoblotting even if ELISA negative.
Important considerations in the assessment of immunoblotting are the criteria used to define a positive result. Band intensity is too variable to be consistently considered5 and the presence of critical bands also vary from study to study.7-9 13-20 Obviously, precise comparisons cannot be made as there are differences in methodology. However, there seems to be significant differences between North American and European results (table 4) which suggests that a major factor is strain diversity, especially in European serum samples. In the USA several bands are frequently reported that are uncommon in Europe: 27-29, 42-46, and 66 and 67 kDa,89 1820 whereas bands at 48-50 and 60 kDa are more common in Europe.5 Our results are consistent with this. The 41 kDa band was present in all our positive immunoblots and also in most negative immunoblots. This is consistent with the hypothesis that this band is a non-specific or genus specific marker,6 but it should be present in all positive results.5 The 20-22 and 30 and 31 kDa bands were more specific. We also identified 55, 70-75 and 92 kDa bands which are not commonly noted by others. Apart from the 92 kDa band, these are considered to be non-specific,6 which our data would seem to support. An interesting finding was the frequency of detection of the 55 kDa band, second only to the 41 kDa band in the positive immunoblots. This band is mentioned by only one other European author,7 13-17 and its common presence in negative immunoblots may be consistent with a local, Highland cross-reacting protein. Also, the fact that in some serum samples we detected bands at 29, 42 and 46 kDa, all of which are rarely reported in Europe, but which are common in the USA, is suggestive of strain variation between the Scottish Highlands and the rest of Europe.
In patients with sequential samples available the IgG band pattern was quite stable over time, although, as might be expected, IgM bands were less frequent in follow up samples. It is interesting that the 55 kDa band is present in four of six patients with arthritis and these patients had frequent exposure to tick bites. When the clinical presentation was considered, immunoblots were most useful in making the diagnosis in patients with arthritis and least useful in patients with ECM.
The media focus on Lyme disease and the large local population of ticks in our area has resulted in a significant increase in sample referrals to this district general hospital. Lyme disease has all of the complexity of a spirochaetal infection. To provide the best diagnostic service, it is important to utilise the full capabilities of the laboratory. Our results demonstrate that ELISA tests alone are insufficient for diagnosing Lyme disease. Despite the cost, it is now imperative that all positive ELISA results are confirmed by immunoblotting. Furthermore, patients with negative or low positive ELISA results but good clinical evidence of Lyme disease, especially those with arthritis, should also be tested by immunoblotting. As immunoblots have to be interpreted according to the banding patterns prevalent in the area of testing, isolation of a local strain of the organism and adapting serological tests (that is, ELISA and immunoblotting) to its antigenic composition would improve serodiagnosis further. The recent use of the polymerase chain reaction to detect B burgdorferi DNA in serum samples4 is also a welcome initiative which requires confirmation. When all these approaches have been fully developed it is likely that laboratory diagnosis will be the equal of this spirochaete.
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